07:00 , Apr 11, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Ret proto-oncogene (RET); KIF5B-RET oncogenic fusion protein ...
07:00 , Apr 11, 2013 |  BC Innovations  |  Cover Story

RET, set, go

Just 15 months after Ret proto-oncogene fusions were first identified in 1%-2% of non-small cell lung cancer cases, early data from a Phase II trial of Exelixis Inc.'s Cometriq cabozantinib suggest that blocking the target...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Clinical News

Cabozantinib: Phase II started

Exelixis said investigators at the Memorial Sloan-Kettering Cancer Center began an open-label, U.S. Phase II trial to evaluate 60 mg oral cabozantinib daily in about 25 NSCLC patients with KIF5B-RET oncogenic fusion protein or...
08:00 , Feb 23, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Ret proto-oncogene (RET); KIF5B-RET oncogenic fusion protein Three separate studies in patient...